The author discusses the approach of U.S.-based Ablexis LLC in developing AlivaMab, humanized mouse technology. He is critical of management of the company who needs new financing to further develop AlivaMab and also highlights that investors were not willing to support long development times and low returns on investment. An overview of deal featuring a consortium of pharmaceutical companies which gives Ablexis working capital to build a mouse is offered.